Effects of Intradermal Botulinum Toxin Injections on Herpes Zoster Related Neuralgia

Abstract

Background

Postherpetic neuralgia (PHN), which represents the most common chronic complication of herpes zoster, is characterized by intense pain and is difficult to treat. In fact, no treatments are currently available that can effectively reduce the pain associated with PHN. Recent evidence has been presented indicating that Botulinum toxin (BoNT-A) can serve as an effective and safe treatment for peripheral neuropathic pain.

Objective

The effects of intradermal BoNT-A injections on herpes zoster related neuralgia were investigated in this study.

Methods

Patients diagnosed with herpes zoster related acute neuralgia (N=13 – acute group) and those diagnosed with postherpetic neuralgia (N=17 - PHN group) were enrolled in this study. The two groups were treated with intradermal injections of BoNT-A at the site of their affected pain areas and were then assessed at 1 day, 1 week, 2 weeks, 1 month, 2 months and 3 months after their BoNT-A treatments.

Results

When compared with pre-treatment values, Visual Analogue Scores (VAS) in all patients were all significantly decreased at all times tested following BoNT-A injection. Before treatment, PHN patients had significantly higher VAS than those in the acute group. However, after 1 day of treatment, there was no difference in VAS between the two groups. None of the patients in the acute phase treated with BoNT-A developed PHN.

Conclusion

BoNT-A injections significantly reduced herpetic-related pain and proved to be a more effective treatment for the PHN versus acute pain group. Moreover, an early application of BoNT-A can alleviate the probability of developing PHN.

Keywords:

• herpes zoster
• postherpetic neuralgia
• botulinum toxin

Introduction

Herpes zoster (HZ), which represents a reactivation of the Varicella-zoster virus (VZV) in the host, has been reported as a possible adverse event in response to COVID-19 vaccination.¹ Postherpetic neuralgia (PHN) is the most common chronic complication of HZ and is characterized by intense pain.² While the pain associated with HZ typically lasts for 2–4 weeks, PHN is defined by a pain that persists for 4–12 weeks.³ At present, it is believed that the pain of PHN is related to pathological changes such as inflammatory edema, scarring or even hemorrhage resulting from damage to peripheral nerve tissue after an acute VZV infection.⁴ Pharmacological treatments for herpes zoster neuralgia include pregabalin, gabapentin, antidepressants, anticonvulsants, carbamazepine, lamotrigine, opioids, and topical lidocaine ointments. However, the evidence for these interventions is often inconclusive,⁵ and the analgesic effect is not obvious. In addition, the side effects associated with these drugs, such as dizziness, ataxia, nausea, vomiting, drowsiness, and rash, can be extremely distressing.⁶ Therefore, it is especially important to seek a drug that provides better pain relief, longer pain relief time and fewer side effects.

Botulinum toxin type A (BoNT-A), produced by C. botulinum in anaerobic laboratory cultures, is a large molecular weight protein of approximately 900,000 daltons. It is comprised of 150,000 daltons of toxic units noncovalently bound to nontoxic proteins that help protect the toxic units against digestive enzymes.⁷

Botulinum toxin (BoNT) is a potent neuromodulator that serves as a highly versatile drug capable of exerting numerous clinical effects as applied for both therapeutic and aesthetic purposes.⁸ The effects of BoNT have been primarily ascribed to its muscle relaxation effects, but it is also widely accepted as a therapeutic procedure in rehabilitation across a range of neurological disorders involving spasticity.⁹ In addition, recent evidence has been presented indicating that BoNT-A is an effective and safe treatment for peripheral neuropathic pain.^10,11

While it has been demonstrated that BoNT-A can be efficacious for the treatment of nerve injury, the specific mechanisms responsible for such effects remain uncertain. Results from recent studies in animal models suggest that botulinum neurotoxin A (BoNT-A) can accelerate nerve regeneration and improve functional recovery after injury to peripheral nerves, with the possible mechanisms proposed for such effects being activation or proliferation of support cells (Schwann cells, mast cells, and macrophages), increased angiogenesis and enhanced blood flow to regenerating nerves.¹² With regard to its effects on pain, some possible mechanisms of BoNT-A include retrograde axonal transport of toxins, inhibition of neuropeptides, such as substance P and calcitonin gene-related protein (CGRP), glutamate and deactivation of Na channels.¹³

In this study, we injected BoNT-A as a treatment for 30 patients with herpes zoster related neuralgia and followed up on the outcomes of this protocol. We also examined the effects of intradermal BoNT-A injections on herpes zoster related neuralgia as involved with PHN.

Materials and Methods

Patients

The Medical Ethics Committee of the Strategic Support Force Medical Center in China approved this study, which was conducted in accordance with the Declaration of Helsinki and all study participants provided informed written consents. All participating patients with herpes zoster and PHN were recruited from the Department of Dermatology of the Strategic Support Force Medical Center. Among these patients, the 13 diagnosed with herpes zoster presenting with neuralgia were treated for the first time and were enrolled into the acute group, while 17 patients were diagnosed with PHN. Our definition of PHN consisted of patients experiencing pain persisting ≥90 days following zoster diagnosis. All patients in this study received famciclovir 250 mg tid for 7 days, Mecobalamin for 1 month and some also received painkillers as requested.

Use of Intradermal Botulinum Toxin

The 30 patients were treated with intradermal injections of BoNT-A at the site of the affected pain areas. Injection sites were distributed in a checkerboard-like pattern, with a space of approximately 1.5–2 cm between two injection sites (Figure 1).

Figure 1 Patients were treated with intradermal injections of BoNT/A at the site of the affected pain areas. Injection sites were distributed in a checkerboard-like pattern, with a space of approximately 1.5–2 cm between two injection sites.

Visual Analogue Score (VAS)

The most frequently used tool for pain measurement in the general population is that of VAS. As this score has been identified as the most sensitive, reproducible and simplest pain scale, it was employed in our current study.

Data Collection

We followed up these patients at 1 day, 1 week, 2 weeks, 1 month, 2 months and 3 months after the BoNT-A treatment. All data, including characteristics of the patients and outcome measures (VAS), were recorded within a questionnaire designed by the investigators of this study. Patients were recruited between May and August of 2020. Each patient underwent a standard assessment procedure and routine follow-up, as performed at 3 months after their BoNT/A injection.

Statistical Analysis

Qualitative variables were expressed as percents and quantitative variables in means ± standard deviations (SD). Data were analyzed using an existing software program (SAS 9.4). To compare the groups at baseline, a t-test was used for quantitative variables and the Fisher’s exact test for qualitative variables. A mixed effect model was used to evaluate VAS between the two groups. The Wilcoxon rank sum test as based on the mixed effect model was used for data failing to demonstrate a normal distribution. A p < 0.05 was required for the results to be considered as statistically significant.

Results

Baseline Population Demographics

Table 1 provides a summary of all the relevant data from the subjects within the acute herpes zoster (N=13; 6 males and 7 females) and PHN (N=17; 9 males and 8 females) groups. Patients in the acute group were slightly younger (median age: 66 years) than those in the PHN group (median age: 70.1 years). Skin lesions were mainly distributed in the region of the trunk, with no significant sex (P=1.00), age (P=0.12) or lesion location (P=0.89) being obtained between the two groups.

Table 1 Summary of Patient Characteristics in Acute and Postherpetic Neuralgia (PHN) Groups

	Acute	PHN	Total	P value
Sex, no (%)
Male	6 (46.15)	9 (52.94)	15 (50)	1.00
Female	7 (53.85)	8 (47.06)	15 (50)
Age, y, mean±SD	66.00 ± 8.46	70.12 ± 5.67	68.33 ± 7.18	0.12
Lesion location (%)
Trunk	10 (76.92)	14 (82.35)	24 (80)	0.89
Upper limbs	2 (15.38)	3 (17.65)	5 (16.67)
Legs	1 (7.69)	0	1 (3.33)

When compared with pre-treatment values, VAS were all significantly decreased at 1 day, 1 week, 2 weeks, 1 month, 2 months and 3 months after botulinum injection in both the acute and PHN groups (Table 2 and Figure 2).

Table 2 Comparisons of Pre- versus Post-Botulinum Toxin VAS as a Function of Different Times Following Treatment in the Acute and PHN Groups

Group	Time	VAS (Mean±SD)	Time	VAS (Mean±SD)	T Value	P value
Acute	Before treatment	4.85±1.41	First day	3.69±1.70	3.72	<0.0001
			First week	2.62±1.71	5.30	<0.0001
			Second week	2.23±1.69	5.31	<0.0001
			First month	1.69±1.65	5.77	<0.0001
			Second month	1.15±1.34	6.28	<0.0001
			Third month	0.69±1.18	6.71	<0.0001
PHN	Before treatment	6.29±1.69	First day	4.88±1.90	5.20	<0.0001
			First week	4.06±2.08	6.08	<0.0001
			Second week	4.06±2.16	5.18	<0.0001
			First month	3.18±2.56	6.52	<0.0001
			Second month	2.82±2.48	6.76	<0.0001
			Third month	2.71±2.64	6.62	<0.0001

Figure 2 Comparisons of VAS before and at varying times post-Botulinum Toxin treatment in the acute and PHN groups.

When comparing VAS between the acute and PHN groups, VAS in the PHN group were significantly higher than that of the acute group before Botulinum Toxin treatment. At one day after Botulinum Toxin treatment, there were no statistically significant differences in VAS between the two groups (Table 3).

Table 3 Comparisons of VAS in the Acute versus PHN Group

	Acute	PHN	P value
VAS	Mean ± SD
Before treatment	4.85±1.41	6.29±1.69	0.04*
First day	3.69±1.70	4.88±1.90	0.10
First week	2.62±1.71	4.06±2.08	0.04*
Second week	2.23±1.69	4.06±2.16	0.01*
First month	1.69±1.65	3.18±2.56	0.04*
Second month	1.15±1.34	2.82±2.48	0.02*
Third month	0.69±1.18	2.71±2.64	0.04*

Note: *P<0.05.

Discussion

In this study, we assessed the capacity for BoNT-A injections to relieve herpetic-related pain. We found that BoNT-A therapy was more effective in the treatment of PHN versus acute pain. When compared with pre-treatment values, Visual Analogue Scores (VAS) in all patients were all significantly decreased at all times tested following BoNT-A injection. Before treatment, PHN patients had significantly higher VAS than those in the acute group. However, after 1 day of treatment, there was no difference in VAS between the two groups. Interestingly, none of the patients using BoNT-A in the acute phase developed PHN, suggesting that an early application of BoNT-A can effectively alleviate the probability of developing PHN.

PHN-associated pain is considered neuropathic.¹⁴ Neuropathic pain (NP) results from a lesion or disease affecting the somatosensory nervous system and encompasses common neurological pain syndromes such as trigeminal neuralgia (TN), postherpetic neuralgia (PHN), diabetic neuropathic pain (DN) and postsurgical neuralgia.¹⁵ With reactivation of varicella zoster virus, there is inflammation of the dorsal root ganglia and nociceptive pathway, with the result that spontaneous discharge and activation thresholds are significantly changed. Pain and temperature detection systems are then hypersensitive to photomechanical stimulation, resulting in severe pain.^16,17 Treatment of PHN consists of an early application of antiviral drugs and topical or systemic use of analgesics. Topical analgesics include a 5% lidocaine patch and capsaicin, systemic analgesics such as gabapentin and opioid analgesics may often be necessary.^18,19 Results from some recent studies have demonstrated that electroacupuncture can be effective in treating the acute pain of Herpes Zoster and low-level laser therapy can reduce the incidence of PHN.^2,20 Moreover, there are some case reports documenting the efficacy of toxins in patients with PHN refractory to conventional treatments in terms of VAS score reduction, with an analgesic duration ranging from 52 to 64 days and a good degree of tolerability.^14,21

However, data regarding the efficacy of BoNT-A on acute pain and PHN of herpes zoster have yet to be presented. Here, we now provide data demonstrating that BoNT-A was effective not only in patients with acute herpes zoster pain and PHN but also reduced the occurrence of herpes zoster PHN.

Botulinum toxin type A has been used for years in the fields of neurology, rehabilitation and physical medicine and has proven to be an innocuous and effective therapy.^13,22 It seems that BoNT-A might also be effective for the comprehensive management of neuropathic pain, especially for diabetic polyneuropathy.²³ BoNT-A can accelerate nerve regeneration and improve functional recovery after injury to peripheral nerves.¹² Moreover, BoNT-A has the capacity to promote wound healing by attenuating the release of norepinephrine and many neurotransmitters, which inhibit vasoconstriction and increase blood flow and, in this way, may exert some positive effects on chronic ulcers. Ischemic ulcers, secondary to Raynaud’s phenomenon, seem to be the most likely type of ulcers that have benefited from BoNT-A.²⁴ Results from a recent study have revealed that an injection of botulinum toxin (BoNT) into the glabellar region of the head served as a novel therapeutic approach for the treatment of depression. The theoretical foundation of BoNT is not specific for depression but may apply to any disorder associated with an excess of negative emotionality.²⁵ Interestingly, there is a case report of a patient experiencing psoriasis and post-stroke spasticity, who demonstrated psoriatic lesion remission following local BoNT-A injections that were administered for the treatment of upper limb spasticity.⁸ Psoriasis is a complex immune-mediated inflammatory disorder which, on the basis of our previous study, was found to involve the nervous system.²⁶

BoNT/A may represent an effective therapeutic option for PHN. Some case-reports documented the efficacy of the toxin in patients with PHN refractory to conventional treatments in terms of VAS score reduction at a mean dose of 100 U, with an analgesic effect duration ranging from 52 to 64 days and a good tolerability.^14,21,27

A long-lasting BoNT/A therapeutic effect has been confirmed in a RCT on 30 adults with PHN in which only the 13 subjects randomized to BoNT/A achieved a >50% reduction in VAS score (NNT=1.2, 95% CI, 2–1; ARR=0.87, 95% CI, 055–096; P<0.001). Notably, BoNT/A improvement in pain and sleep scores persisted for 16 weeks.²⁸

These studies of injectable botulinum toxin type A for postherpetic neuralgia were similar to our trial results.

The clinical utility of BoNT-A originates from its ability to block muscular contractions by inhibiting neurotransmission between peripheral nerve cells and muscle fibers.²⁹ For example, BoNT-A has been shown to inhibit the release of calcitonin gene-related peptide (CGRP) and Substance P (SP).¹³ When BoNT-A enters nerve cells, its capacity for division prevents acetylcholine release into the neuromuscular junction and thus blocks muscle fiber contraction.³⁰ And, when injected into the subcutaneous region of the dermis, BoNT-A reduced acetylcholine release from autonomic nerve terminals. BoNT-A has also been used as a safe and effective method to enhance primary focal hyperhidrosis in armpits, palms and feet due to its ability to reduce the hyperactive function of eccrine glands.³¹ However, the underlying mechanisms of BoNT-A in the treatment of herpes zoster related neuralgia are not clear. Some possible mechanisms may include a retrograde axonal transport of the toxin, inhibition of neuropeptides, such as substance P and calcitonin gene-related protein (CGRP), glutamate and deactivation of Na channels.¹³ Each of these possible mechanisms warrant further investigation.

This study has some limitations. Notably, it suffers from a lack of a double-blind randomization and placebo control. There is also a possibility for selection bias in this study, as patients with more serious concomitant diseases were not enrolled in this study. However, in our observations, patients with more severe PHN and more extensive rash tended to receive an injection of BoNT-A as an alternative treatment. Therefore, more randomized controlled trials will be required to corroborate and substantiate our results.

Disclosure

The authors report no conflicts of interest in this work.